Pillar Biosciences Incorporated

New White Paper, Now Live! Check out our latest white paper: "Targeted NGS as a Frontline Strategy to Accelerate the Precision Treatment of Solid and Heme Tumors". Discover how leading cancer centers are using targeted NGS to: - Streamline tumor profiling - Achieve rapid turnaround times - Consolidate biomarker testing Featuring insights from experts at MSK and USC Keck Hospital. Don't miss this opportunity to learn about cutting-edge approaches and advancing our mission of Decision Medicine™ 👉Download the white paper now! https://lnkd.in/eGMmZpUS

🚀 In 2024, Pillar Biosciences made significant strides in advancing our mission of Decision Medicine™ and improving cancer diagnostics through rapid, innovative Next-Generation Sequencing (NGS) kitted solutions. We've made substantial advancements and improved access to precision oncology solutions globally. As we step into 2025, let's celebrate the milestones we've achieved together in 2024. ✨ Highlights include: * Innovative product launches * Strategic partnerships that have expanded our reach * Significant contributions and advancements in Next-Generation Sequencing (NGS) technology and oncology diagnostics. Join us in looking back at our accomplishments and envisioning an even brighter future. Check out our full Year in Review to see how we're shaping the future of biosciences! 👉 Read more here: https://lnkd.in/eacR-t2S

Pillar Biosciences Incorporated has entered into a licensing agreement for Memorial Sloan Kettering Cancer Center's OncoKB™ Precision Medicine Knowledgebase. OncoKB™ is the first somatic human variant database to receive FDA recognition. It contains information about the biological effects and possible treatment implications of specific cancer gene alterations.  The strategic licensing agreement enables immediate extension of the capability of Pillar Biosciences PiVAT® bioinformatics platform for seamless patient genomic reporting through linkage to OncoKB™. https://lnkd.in/gR9H2JpX

It's not too late to register for our upcoming December webinar hosted by GenomeWeb this Thursday, December 5th at 8 am PST. Join us for an insightful session with Dr. Mark Ewalt, MD and @Dr. Pamela Ward, PhD as they explore Pillar Biosciences' oncoReveal Nexus 21 Gene panel and the clinical need for a rapid targeted NGS panel as a complement to CGP. Discover real-world implementation data from USC Keck Hospital, Norris Comprehensive Cancer Center and Memorial Sloan Kettering Cancer Center. Don't miss this opportunity to revolutionize your lab's cancer diagnostics! Register now: https://lnkd.in/e6KMEhet

🧬Exciting Webinar, Next Thursday, December 5th! 🔬 Join us on Thursday, December 5th for an insightful session with Dr. Mark Ewalt, MD and Dr. Pamela Ward, PhD as they explore targeted NGS as a front-line strategy to accelerate the delivery of precision medicine for solid and heme tumors. • Discover real-world implementation data from USC Keck Hospital, Norris Comprehensive Cancer Center, and MSK. • Learn how rapid targeted NGS testing can be leveraged as a tool to help sub-select and inform which patients should have follow-on CGP testing. • Understand how Pillar Biosciences' oncoReveal Nexus 21 Gene panel can be used by laboratories to streamline the use of single-gene PCR testing. Register today: https://lnkd.in/e6KMEhet

Did you miss any of our scientific poster presentations or do you want to learn more about the scientific data presented? Poster and abstract summaries of the research presented in the ten scientific posters featuring Pillar Biosciences Incorporated will be available at our #AMP2024 Booth #1307. Please stop by to ask questions or for more information.

Explore ten scientific posters highlighting Pillar Biosciences' oncoReveal suite of kitted NGS solutions this Friday and Saturday at #AMP2024. Topics covered include: • Clinical validation of oncoReveal CDx, our FDA-approved pan-cancer solid tumor IVD assay • Validation of our rapid, targeted NGS panels • Performance insights on our Essential MPN Panel • Automation of our panels using state-of-the-art library prep systems Join us to see how Pillar Biosciences is empowering laboratories with simple, fast, and accurate NGS solutions. See the full schedule below.

Are you planning your agenda for #AMP2024 this week? Don't miss the chance to explore ten innovative studies featuring Pillar Biosciences Incorporated and our innovative NGS platform technology! With automated workflows and rapid results, we're revolutionizing localized testing for both research and clinical applications with our oncoReveal suite of kitted NGS products. ⭐ Don’t miss Dr. Audrey Roy's platform presentation on the “Validation of a Rapid Targeted NGS Oncology Panel” kicking us off today at 3:00 PM PST in Room 118/120. #NGSTechnology #NGSPlatform

Don't miss our 3rd and final Corporate Workshop of the day: "Expanding PARPi Therapy in Breast Cancer: Insights from Pillar Biosciences' Rapid oncoReveal 4-Gene Methylation Panel" Dr. Sophie Kirschner from AstraZeneca will present scientific research data on expanding PARPi therapy in breast cancer using Pillar Biosciences' rapid oncoReveal 4-Gene Methylation Panel. This rapid (RUO) NGS panel detects HR proficiency restoration and potential PARPi resistance, going beyond traditional HRD scoring. Join the workshop in Room 111/112 at 12 PM, PST #AMP2024

📅 Today at 9:00 AM, PST in Room 221/222 Join us for our second Corporate Workshop of the day at AMP 2024: “Leveraging Pillar Biosciences Targeted NGS Panels for Rapid Front-Line Precision Medicine." Presented by Dr. Mark Ewalt, MD, of Memorial Sloan Kettering Cancer Center, this session will explore: • Development and validation of oncoReveal Nexus • Clinical implementation at MSK • Concordance with MSK-IMPACT® panels • Strategies for rapid patient selection Join us for this insightful workshop and learn how targeted NGS panels can enhance precision medicine and streamline patient selection for comprehensive genomic profiling (CGP) testing! #AMP2024